產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-PDZD9抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-PDZD9抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-PDZD9
Cat. Number:
Anti-PDZD9抗體KL-9632R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PDZD9 (PDZ domain containing 9) is a 264 amino acid protein that contains one PDZ (DHR) domain and participates in protein binding. Conserved in chimpanzee, dog, cow, mouse and rat, PDZD9 exists as two alternatively spliced isoforms and is encoded by a gene that maps to human chromosome 16p12.1.Anti-PDZD9抗體 Chromosome 16 encodes over 900 genes, approximately 90 million base pairs, makes up nearly 3% of human cellular DNA and is associated with a variety of genetic disorders. Giant axonal neuropathy, a nervous system disorder characterized by increasing malfunction with growth, and the rare disorder Rubinstein-Taybi syndrome, characterized by mental retardation and predisposition to tumor growth and white blood cell neoplasias, are associated with chromosome 16. Crohn's disease, a gastrointestinal inflammatory condition, and systemic lupus erythematosis are also associated with chromosome 16.
Also known as:
PDZ domain containing 9; PDZ Anti-PDZD9抗體domain containing protein 9; PDZD 9; PDZK-9.\; PDZD9_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Horse, Rabbit, .
●
Immunogen: KLH conjugated Anti-PDZD9抗體synthetic peptide derived from human PDZD9.
●
Predicted Molecular Weight: 30kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-PDZD9抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-PDZD9抗體
Optimal working dilutions must be determined by the end user.
